NI200600146A - Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso - Google Patents

Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso

Info

Publication number
NI200600146A
NI200600146A NI200600146A NI200600146A NI200600146A NI 200600146 A NI200600146 A NI 200600146A NI 200600146 A NI200600146 A NI 200600146A NI 200600146 A NI200600146 A NI 200600146A NI 200600146 A NI200600146 A NI 200600146A
Authority
NI
Nicaragua
Prior art keywords
pharmaceutical composition
parenteral administration
preparation process
vinflunine
vinflunine pharmaceutical
Prior art date
Application number
NI200600146A
Other languages
English (en)
Inventor
Elie Leverd
Joel Bougaret
Marie-Dominique Ibarra
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34630533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI200600146(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of NI200600146A publication Critical patent/NI200600146A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica de vinflunina en forma de una solución acuosa estable y estéril de una sal de vinflunina soluble en agua, a un PH de entre 3 y 4. La invención además se refiere al proceso para la preparación de esta composición, y a su uso como una especialidad medicinal para administración parenteral, en el tratamiento de cáncer.
NI200600146A 2003-12-23 2006-06-23 Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso NI200600146A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0315312A FR2863891B1 (fr) 2003-12-23 2003-12-23 Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation

Publications (1)

Publication Number Publication Date
NI200600146A true NI200600146A (es) 2006-12-12

Family

ID=34630533

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200600146A NI200600146A (es) 2003-12-23 2006-06-23 Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso

Country Status (35)

Country Link
US (1) US20070155768A1 (es)
EP (1) EP1696913B1 (es)
JP (2) JP5226220B2 (es)
KR (1) KR101166347B1 (es)
CN (2) CN1897940A (es)
AR (1) AR047346A1 (es)
AT (1) ATE424201T1 (es)
AU (1) AU2004314154B2 (es)
BR (1) BRPI0418005B8 (es)
CA (1) CA2551493C (es)
CR (1) CR8473A (es)
CY (1) CY1109120T1 (es)
DE (1) DE602004019809D1 (es)
DK (1) DK1696913T3 (es)
EC (1) ECSP066663A (es)
ES (1) ES2323374T3 (es)
FR (1) FR2863891B1 (es)
HK (1) HK1089105A1 (es)
IL (1) IL176404A (es)
MA (1) MA28237A1 (es)
MX (1) MXPA06007208A (es)
MY (1) MY139643A (es)
NI (1) NI200600146A (es)
NO (1) NO336427B1 (es)
NZ (1) NZ548028A (es)
OA (1) OA13348A (es)
PL (1) PL1696913T3 (es)
PT (1) PT1696913E (es)
RU (1) RU2362557C2 (es)
SI (1) SI1696913T1 (es)
TN (1) TNSN06197A1 (es)
TW (1) TWI334352B (es)
UA (1) UA83888C2 (es)
WO (1) WO2005070425A1 (es)
ZA (1) ZA200605201B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110015221A1 (en) * 2003-12-23 2011-01-20 Pierre Fabre Medicament Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
FR2910812B1 (fr) 2006-12-29 2009-03-20 Pierre Fabre Medicament Sa Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
FR2912406B1 (fr) * 2007-02-13 2009-05-08 Pierre Fabre Medicament Sa Sels cristalins anhydres de vinflunine, procede de preparation et utilisation en tant que medicament et moyen de purification de la vinflunine.
EP1997534A1 (en) * 2007-05-31 2008-12-03 Pierre Fabre Medicament Cancer treatment combination therapy comprising vinflunine and trastuzumab
CN101129374B (zh) * 2007-06-26 2010-09-08 齐鲁制药有限公司 长春氟宁药物组合物及其制备方法与应用
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
FR2918566B1 (fr) * 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
CN101607968A (zh) * 2008-06-17 2009-12-23 江苏豪森药业股份有限公司 长春氟宁盐、其制备方法及其药物组合物
UY33975A (es) * 2011-03-29 2012-10-31 Sanofi Sa Formulaciones de otamixaban con estabilidad mejorada
EP3777861A1 (en) * 2015-08-01 2021-02-17 Sun Pharmaceutical Industries Ltd Dosage form of vinca alkaloid drug
WO2018007554A1 (en) * 2016-07-06 2018-01-11 Pierre Fabre Medicament Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307100A (en) * 1978-08-24 1981-12-22 Agence Nationale De Valorisation De La Recherche (Anvar) Nor bis-indole compounds usable as medicaments
US4619935A (en) * 1983-03-17 1986-10-28 Eli Lilly And Company Stable oncolytic formulations
HU195513B (en) * 1984-10-16 1988-05-30 Richter Gedeon Vegyeszet Process for producing stable solutions of alkaloides with bis-indole skeleton
FR2597750B1 (fr) * 1986-04-25 1989-06-02 Pf Medicament Solution aqueuse stable de sulfate de vincristine
IL83086A (en) * 1987-07-06 1991-03-10 Teva Pharma Stable,injectable solutions of vincristine salts
US4923876A (en) * 1988-04-18 1990-05-08 Cetus Corporation Vinca alkaloid pharmaceutical compositions
CA2001643A1 (en) * 1988-12-23 1990-06-23 Richard L. Wolgemuth Preservative-free multi-dose vincristine solution
HU204995B (en) * 1989-11-07 1992-03-30 Richter Gedeon Vegyeszet Process for producing pharmaceutical composition comprising alkaloid with bis-indole skeleton, with antitumour activity and suitable fr parenteral purposes
JPH06100452A (ja) * 1993-04-06 1994-04-12 Asta Medica Ag イホスファミド用の製薬学的容器
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
DE19706255C2 (de) * 1997-02-18 2000-11-30 Schott Glas Sterilisierbarer Glasbehälter für medizinische Zwecke, insbesondere zur Aufbewahrung pharmazeutischer oder diagnostischer Produkte
FR2761990B1 (fr) * 1997-04-10 1999-06-25 Pf Medicament Derives halogenes antimitotiques d'alcaloides de vinca
JP3642492B1 (ja) * 2003-10-31 2005-04-27 小野薬品工業株式会社 オザグレルナトリウム含有水溶液を充填してなる注射用容器
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation

Also Published As

Publication number Publication date
UA83888C2 (ru) 2008-08-26
DK1696913T3 (da) 2009-06-29
SI1696913T1 (sl) 2009-08-31
ATE424201T1 (de) 2009-03-15
DE602004019809D1 (de) 2009-04-16
NZ548028A (en) 2010-01-29
JP5226220B2 (ja) 2013-07-03
KR101166347B1 (ko) 2012-07-18
JP5710462B2 (ja) 2015-04-30
TW200531717A (en) 2005-10-01
EP1696913A1 (fr) 2006-09-06
FR2863891A1 (fr) 2005-06-24
BRPI0418005A (pt) 2007-04-17
EP1696913B1 (fr) 2009-03-04
TNSN06197A1 (fr) 2007-11-15
WO2005070425A1 (fr) 2005-08-04
MY139643A (en) 2009-10-30
ES2323374T3 (es) 2009-07-14
BRPI0418005B1 (pt) 2019-11-26
MA28237A1 (fr) 2006-10-02
KR20060124624A (ko) 2006-12-05
OA13348A (fr) 2007-04-13
HK1089105A1 (en) 2006-11-24
AU2004314154B2 (en) 2011-03-24
ECSP066663A (es) 2006-10-25
CY1109120T1 (el) 2014-07-02
PT1696913E (pt) 2009-06-05
NO336427B1 (no) 2015-08-17
RU2362557C2 (ru) 2009-07-27
MXPA06007208A (es) 2006-08-18
RU2006126708A (ru) 2008-01-27
AR047346A1 (es) 2006-01-18
IL176404A (en) 2010-11-30
FR2863891B1 (fr) 2006-03-24
CA2551493A1 (fr) 2005-08-04
BRPI0418005B8 (pt) 2021-05-25
NO20063277L (no) 2006-07-14
TWI334352B (en) 2010-12-11
IL176404A0 (en) 2006-10-05
JP2007515461A (ja) 2007-06-14
CN101695474A (zh) 2010-04-21
JP2012102120A (ja) 2012-05-31
ZA200605201B (en) 2007-09-26
US20070155768A1 (en) 2007-07-05
CN1897940A (zh) 2007-01-17
PL1696913T3 (pl) 2009-08-31
CR8473A (es) 2006-11-24
AU2004314154A1 (en) 2005-08-04
CA2551493C (fr) 2012-12-04

Similar Documents

Publication Publication Date Title
NI200600146A (es) Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
NO20075136L (no) Nye liposompreparater
BRPI0608853B8 (pt) composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes
MXPA05011208A (es) Uso de ivermectina para el tratamiento de desordenes dermatologicos.
UA91512C2 (ru) Коньюгати олигомеров инсулина, их композиция (варианты) и применение
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
CU23367A3 (es) Formulación de moxifloxacino con sal común
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
WO2005097135A3 (en) Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives
WO2005072061A3 (en) Conjugates for cancer therapy and diagnosis
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
WO2006131923A3 (en) Novel salts of conjugated psychotropic drugs and processes of preparing same
PE20010623A1 (es) Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
SE0300098D0 (sv) Use of cyclin D1 inhibitors
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
DE60137069D1 (de) Arzneizusammensetzungen enthaltend modafinilverbindungen
BRPI0411702B8 (pt) uso de ácido hialurônico para preparar composições para o tratamento de aftas da cavidade oral
PE20050189A1 (es) Composiciones que comprenden derivados de acido quinoloncarboxilico para administracion local
BRPI0507811A (pt) derivados de 7h-pirrolopirimidina
BRPI0512151A (pt) solução concentrada de sal de sódio monoidratado do tenatoprazol, composição farmacêutica, utilização do sal de sódio monoidratado do tenatoprazol, processo de preparação do sal de sódio monoidratado do tenatoprazol, e composição para administração por via oral do sal de sódio monoidratado do tenatoprazol
UA88884C2 (ru) Набор для приготовления фармацевтических композиций цис-оксоплатина, фармацевтическая композиция и ее применение при лечении рака
TW200626133A (en) Oral medication for twice-daily administration